LMP-420: A novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells

Leukemia

Volumn 24, Issue 9, 2010, Pages 1580-1587

  Mowery, Y M ^a   Weinberg, J B ^a,b   Kennedy, M N ^a   Bond, K M ^b   Moore, J O ^a   Lanasa, M C ^a   Gockerman, J P ^a   Diehl, L F ^a   Pizzo, S V ^a   Cianciolo, G J ^a   Friedman, D R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

apoptosis; chronic lymphocytic leukemia (CLL); hematopoietic toxicity; LMP 420; nuclear factor B (NF B); tumor necrosis factor (TNF)

Indexed keywords

BAG 1 PROTEIN; BENDAMUSTINE; CASPASE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; LMP 420; PENTOSTATIN; PREDNISONE; PROTEIN BCL XL; PROTEIN MCL 1; PURINE NUCLEOSIDE DERIVATIVE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; 2-AMINO-6-CHLORO-9-((5-DIHYDROXYBORYL)PENTYL)PURINE; ANTINEOPLASTIC AGENT; BORON DERIVATIVE; PURINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; VIDARABINE;

ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER PATIENT; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; COLONY FORMATION; CYTOTOXICITY; DNA FRAGMENTATION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION PROFILING; HEMATOPOIETIC CELL; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; LEUKEMIA CELL; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; T LYMPHOCYTE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FLOW CYTOMETRY; GENETICS; PATHOLOGY; TOXICITY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORON COMPOUNDS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; PROGNOSIS; PURINES; TUMOR NECROSIS FACTOR-ALPHA; VIDARABINE;

EID: 77956426657     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.150     Document Type: Article

References (41)

1. Wierda W, OBrien S, Wen S, Faderl S, Garcia-Manero G, Thomas D et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070-4078. (Pubitemid 46211312)
2. Tam CS, OBrien S, Wierda W, Kantarjian H, Wen S, Do K-A et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975-980.
3. Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol 2006; 33: 240-249.
4. Foa R, Massaia M, Cardona S, Tos AG, Bianchi A, Attisano C et al. Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood 1990; 76: 393-400.
5. Digel W, Stefanic M, Schoniger W, Buck C, Raghavachar A, Frickhofen N et al. Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia. Blood 1989; 73: 1242-1246.
6. Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 2002; 100: 1215-1219.
7. Hale L, Cianciolo G. Treatment of experimental colitis in mice with LMP-420, an inhibitor of TNF transcription. J Inflamm 2008; 5: 4.
8. Haraguchi S, Day N, Kamchaisatian W, Beigier-Pompadre M, Stenger S, Tangsinmankong N et al. LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and mycobacterium tuberculosis in human cells. AIDS Res Therapy 2006; 3: 8.
9. Woyach JA, Lin TS, Lucas MS, Heerema N, Moran ME, Cheney C et al. A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia 2009; 23: 912-918.
10. Tsimberidou AM, Thomas D, OBrien S, Andreeff M, Kurzrock R, Keating M et al. Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. Cancer Chemother Pharmacol 2002; 50: 237-242.
11. Weinberg JB, Volkheimer AD, Chen Y, Beasley BE, Jiang N, Lanasa MC et al. Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. Am J Hematol 2007; 82: 1063-1070.
12. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916. (Pubitemid 32064784)
13. Adams DJ, Levesque MC, Weinberg JB, Smith KL, Flowers JL, Moore J et al. Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes. Leukemia 2001; 15: 1852-1859.
14. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996; 2: 574-577.
15. Thomas D, Folker S, Manuela K, Tobias D, Grayson BL, Hermann W et al. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. Exp Hematol 2000; 28: 558-568.
16. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8: 118-127.
17. Chang JT, Nevins JR. GATHER: a systems approach to interpreting genomic signatures. Bioinformatics 2006; 22: 2926-2933.
18. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353-357.
19. Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980; 68: 251-306.
20. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2777-2783.
21. Reittie JE, Yong KL, Panayiotidis P, Hoffbrand AV. Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia. Leuk Lymphoma 1996; 22: 83-90, , follow 186, color plate VI.
22. Tangye SG, Raison RL. Human cytokines suppress apoptosis of leukaemic CD5+ B cells and preserve expression of bcl-2. Immunol Cell Biol 1997; 75: 127-135.
23. Buschle M, Campana D, Carding SR, Richard C, Hoffbrand AV, Brenner MK. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med 1993; 177: 213-218.
24. Grdisa M. Influence of CD40 ligation on survival and apoptosis of B-CLL cells in vitro. Leuk Res 2003; 27: 951-956.
25. Luqman M, Klabunde S, Lin K, Georgakis GV, Cherukuri A, Holash J et al. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 2008; 112: 711-720.
26. Schattner EJ, Mascarenhas J, Reyfman I, Koshy M, Woo C, Friedman SM et al. Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity. Blood 1998; 91: 2689-2697.
27. Chiorazzi N. Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. Best Pract Res Clin Haematol 2007; 20: 399-413.
28. Longo PG, Laurenti L, Gobessi S, Petlickovski A, Pelosi M, Chiusolo P et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 2006; 21: 110-120.
29. Li X, Bu X, Lu B, Avraham H, Flavell RA, Lim B. The hematopoiesis- specific GTP-binding protein RhoH is GTPase deficient and modulates activities of other Rho GTPases by an inhibitory function. Mol Cell Biol 2002; 22: 1158-1171.
30. Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009; 137: 1062-1075.
31. Furman RR, Asgary Z, Mascarenhas JO, Liou H-C, Schattner EJ. Modulation of NF-κB activity and apoptosis in chronic. J Immunol 2000; 164: 2200-2206.
32. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E et al. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med 2003; 198: 1043-1055.
33. Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998; 91: 4624-4631.
34. Pepper C, Hewamana S, Brennan P, Fegan C. NF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia. Future Oncol 2009; 5: 1027-1037.
35. Pickering BM, de Mel S, Lee M, Howell M, Habens F, Dallman CL et al. Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene 2007; 26: 1166-1177.
36. Van Den Neste E, Bontemps F, Delacauw A, Cardoen S, Louviaux I, Scheiff JM et al. Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-20-deoxyadenosine. Leukemia 1999; 13: 918-925.
37. Schwanen C, Hecker T, Hubinger G, Wolfle M, Rittgen W, Bergmann L et al. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 2002; 16: 2096-2105.
38. Silber R, Degar B, Costin D, Newcomb EW, Mani M, Rosenberg CR et al. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood 1994; 84: 3440-3446.
39. Morabito F, Stelitano C, Callea I, Filangeri M, Oliva B, Sculli G et al. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features. Haematologica 1996; 81: 224-231.
40. Johnston JB, Paul JT, Neufeld NJ, Haney N, Kropp DM, Hu X et al. Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia. Leuk Lymphoma 2004; 45: 2017-2027.
41. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379-3389.